Navigation Links
Mouse model for mesothelioma reproduces human disease
Date:3/10/2008

Scientists have established a mouse model for human malignant mesothelioma (MM) that will provide valuable insight into cancer development and progression along with new directions for design of therapeutic strategies. The research, published by Cell Press in the March issue of Cancer Cell, may eventually lead to a substantially improved outlook for patients with this devastating disease.

MM is an aggressive cancer originating from the mesothelial lining of the pleural cavity. MM is associated with asbestos exposure and is characterized by a long latency period between exposure and disease onset. Chemotherapy can sometimes lead to improvement of overall survival but there is no cure for MM and patients often succumb from the disease within a year of diagnosis. There is an urgent need for experimental models of MM that can be used to not only study the onset and progression of the disease, but also to serve as a model to select new combination therapies and targeted agents, says study leader, Dr. Anton Berns, from The Netherlands Cancer Institute.

In humans, MM has been associated with genetic lesions that result in the loss of Neurofibromatosis type 2 (NF2) and genetic lesions affecting RB and P53 pathways. Dr. Berns team investigated whether a range of conditional single or compound mutations in the Nf2, p53 and Rb pathways within the mesothelial lining of the thoracic cavity would cause MM in mice.

The researchers found that the vast majority of mice with conditional Nf2;Ink4a/Arf and Nf2;p53 mutations developed MM after a short latency period. The mouse MM tumors, which could be followed noninvasively through the use of bioluminescence imaging, closely resembled human MM. Interestingly, Nf2;Ink4a/Arf knockout mice had a more invasive cancer when compared with Nf2;p53 knockout mice. The researchers went on to show that the loss of Ink4a makes a substantial contribution to the poor clinical outcome of murine MM.

These results describe an excellent model system for investigating the molecular mechanisms that underlie MM. Our mouse models should be suitable to further dissect pathways critically important in mesothelioma development and progression and serve as invaluable tools to test new intervention strategies, concludes Dr. Berns. We have also derived a series of cell lines that reproduce the disease when grafted into the thoracic cavity. These may also facilitate design of better MM therapies.


'/>"/>

Contact: Cathleen Genova
cgenova@cell.com
617-397-2802
Cell Press
Source:Eurekalert

Related medicine news :

1. Mouse study: Real-time imaging device may improve surgery for congenital colon disease
2. Seal Shield Introduces New Silver Seal Washable, Antimicrobial Mouse at HiMSS Healthcare Symposium
3. Mouse Model of Age-Related Macular Degeneration Developed
4. Gene Tweak Reverses Aging in Mouse Skin Cells
5. A longer-living, healthier mouse that could hold clues to human aging
6. Mouse mammary tumor virus can replicate in human cells
7. Mouse Study Gives Clues to Colitis
8. Mouse vision has a rhythm all its own
9. Effectiveness of mouse breeds that mimic Alzheimers disease symptoms questioned
10. Liko Introduces New LowBase(TM) Model of Its Popular Golvo Mobile Lift
11. UCSF researchers validate new model for breast cancer risk assessment in multiple ethnic groups
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... (PRWEB) , ... December 02, 2016 , ... ... will give patients better access to nutraceuticals and help doctors more efficiently manage ... patient portal and practice management software platform for Integrative and Functional Medicine. ...
(Date:12/4/2016)... ... December 03, 2016 , ... ... at the 2016 Anti-Aging & Beauty Awards at The Aesthetic & ... & Anti-Aging Medicine European Congress (AMEC) brings together the industry’s leading scientific ...
(Date:12/4/2016)... ... December 04, 2016 , ... Are You Concerned About Mold ... certified and experienced Indoor Air Quality Companies in VA, MD and DC, recently completed ... , The new mold law in the district of Columbia is a good ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... ... documentary on the perils of heroin that was watched live by 1 million ... Alfred I. duPont-Columbia University Award. , ASU students at the Walter Cronkite School ...
(Date:12/2/2016)... ... , ... Advanced Inc., a leading provider of travel therapy and travel nursing ... as Advanced Inc.’s Chief Financial Officer, effective December 1, 2016. Jason previously served as ... operational leadership experience to Advanced Inc. He began his career in finance at Ernst ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... Israel , December 5, 2016 ... identifying, in-licensing and developing promising therapeutic candidates, presents positive Phase ... BL-8040, the Company,s leading oncology platform at the ongoing 58th ... San Diego, California . ... , , ...
(Date:12/5/2016)... Taiwan , Dec. 5, 2016 ... non-inferiority to hydroxyurea (HU) in Complete Hematologic Response (CHR) ... profile of ropeginterferon alfa-2b versus HU AOP ... follow-up trial CONTINUATION-PV to obtain European marketing authorization in the ... data to the FDA as it seeks approval for commercialization ...
(Date:12/4/2016)... --  Pairnomix, LLC, a genetic research company and member ... White House, today announced that findings from its first case ... therapies for a patient with epileptic encephalopathy caused by a ... the 70 th Annual Meeting of the American ... December 2-6, 2016.  Pairnomix, unique process involves creating ...
Breaking Medicine Technology: